To investigate the minimal requirement for the tumor cellular index to evaluate the appropriate drug response, we seeded a mixture of HER2-positive gastric cancer cells with non-neoplastic cells at various concentrations (from 1 to 90%) and treated the cells with lapatinib. Here, ERBB2 is linked to gastric cancer.